UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (8), p.2773-2778

2008

Volltextzugriff (PDF)

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.909-920

2012

Volltextzugriff (PDF)

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors

Bioorganic & medicinal chemistry letters, 2009-03, Vol.19 (5), p.1332-1336

2009

Volltextzugriff (PDF)

Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2- d]pyrimidines

Bioorganic & medicinal chemistry, 2008-11, Vol.18 (21), p.5738-5740

2008

Volltextzugriff (PDF)

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Cancer research (Chicago, Ill.), 2004-09, Vol.64 (18), p.6652-6659

2004

Volltextzugriff (PDF)

Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor

Proceedings of the National Academy of Sciences - PNAS, 2005-03, Vol.102 (10), p.3587-3592

2005

Volltextzugriff (PDF)

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B‑Raf-Driven Tumors

ACS medicinal chemistry letters, 2013-03, Vol.4 (3), p.358-362

2013

Volltextzugriff (PDF)

Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2- d]pyrimidines as EGFR and ErbB-2 inhibitors

Bioorganic & medicinal chemistry letters, 2009, Vol.19 (1), p.21-26

2009

Volltextzugriff (PDF)

The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors

Bioorganic & medicinal chemistry letters, 2013-01, Vol.23 (1), p.66-70

2013

Volltextzugriff (PDF)

Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis

Journal of medicinal chemistry, 2001-12, Vol.44 (25), p.4339-4358

2001

Volltextzugriff (PDF)

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.817-820

2009

Volltextzugriff (PDF)

Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors

Bioorganic & medicinal chemistry, 2008-08, Vol.18 (16), p.4610-4614

2008

Volltextzugriff (PDF)

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4716-4730

2004

Volltextzugriff (PDF)

Discovery and optimization of imidazo[1,2- a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.1004-1008

2009

Volltextzugriff (PDF)

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (9), p.2121-2125

2004

Volltextzugriff (PDF)

Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (4), p.1177-1182

2009

Volltextzugriff (PDF)

Novel GSK-3 inhibitors with improved cellular activity

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (9), p.2127-2130

2004

Volltextzugriff (PDF)

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup

Bioorganic & medicinal chemistry letters, 2011-08, Vol.21 (15), p.4436-4440

2011

Volltextzugriff (PDF)

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.981-985

2009

Volltextzugriff (PDF)

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.976-980

2009

Volltextzugriff (PDF)

Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors

Bioorganic & medicinal chemistry letters, 2006-05, Vol.16 (9), p.2419-2422

2006

Volltextzugriff (PDF)

Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase

Cancer research (Chicago, Ill.), 1993-02, Vol.53 (4), p.810-818

1993

Volltextzugriff (PDF)

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Cancer research (Chicago, Ill.), 2004-09, Vol.64 (18), p.6652-6659

2004

Volltextzugriff (PDF)

Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones

Journal of medicinal chemistry, 1993-08, Vol.36 (16), p.2279-2291

1993

Volltextzugriff (PDF)

Benzo[f]quinazoline Inhibitors of Thymidylate Synthase: Methyleneamino-Linked Aroylglutamate Derivatives

Journal of medicinal chemistry, 1994-03, Vol.37 (6), p.838-844

1994

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(87)
Tagungsberichte
(5)

Sprache

Englisch
(92)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors

Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2- d]pyrimidines

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B‑Raf-Driven Tumors

Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2- d]pyrimidines as EGFR and ErbB-2 inhibitors

The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors

Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy

Discovery and optimization of imidazo[1,2- a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors

Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy

Novel GSK-3 inhibitors with improved cellular activity

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups

Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors

Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones

Benzo[f]quinazoline Inhibitors of Thymidylate Synthase: Methyleneamino-Linked Aroylglutamate Derivatives

Suchergebnisse filtern